Intersect ENT Announces Preliminary Q2 Revenue and Business Update

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced preliminary revenue for the second quarter 2016 of approximately $19.3 million, an increase of 27% from the second quarter 2015.

Back to news